TY - JOUR
T1 - Left ventricular mass as a predictor of cardiovascular events in the era of hypertension management using home blood pressure measurement
T2 - the J-HOP study
AU - Waki, Hirotaka
AU - Hoshide, Satoshi
AU - Kario, Kazuomi
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to The Japanese Society of Hypertension.
PY - 2022/8
Y1 - 2022/8
N2 - Target organ damage (TOD) is associated with a risk of cardiovascular disease (CVD) independent of blood pressure (BP); however, this association has been observed based on the assessment of office BP. We studied 1641 patients (mean age 64.8 ± 11.7 years) with CVD risk factors who underwent home BP measurement over a 14-day period and evaluated TOD at baseline and then performed follow-up examination of the J-HOP (Japan Morning Surge-Home Blood Pressure) study results. During the median follow-up of 6.6 ± 3.5 years, 115 participants experienced a CVD event. After adjustment for CVD risk factors, including office systolic BP, the adjusted hazard ratios expressing the risk of CVD events were 1.30 (95% confidence interval, 1.15–1.52), 1.27 (1.04–1.56), and 1.25 (1.11–1.40) per one-SD increase in log-transformed urinary albumin creatinine ratio (UACR, 0.57 mg/gCre), brachial-ankle pulse wave velocity (baPWV, 342 cm/s) and left ventricular mass index (LVMI, 26.6 g/m2) assessed by echocardiography, respectively. Even after adding home systolic BP as a covariate, these associations remained except for the association with baPWV (all P < 0.05). The C-statistic for the base model including office and home systolic BP for the risk of CVD events was 0.783 (95% CI: 0.743, 0.824), which significantly increased to 0.795 (95% CI: 0.757, 0.834) after adding LVMI, and changed slightly but not significantly with the addition of UACR or baPWV. Adding UACR, baPWV, or both to the model including LVMI did not improve CVD event prediction. In the modern era of hypertension management using home BP measurement, TOD indicators, especially LVMI, provide superior CVD event prediction independent of and beyond home BP.
AB - Target organ damage (TOD) is associated with a risk of cardiovascular disease (CVD) independent of blood pressure (BP); however, this association has been observed based on the assessment of office BP. We studied 1641 patients (mean age 64.8 ± 11.7 years) with CVD risk factors who underwent home BP measurement over a 14-day period and evaluated TOD at baseline and then performed follow-up examination of the J-HOP (Japan Morning Surge-Home Blood Pressure) study results. During the median follow-up of 6.6 ± 3.5 years, 115 participants experienced a CVD event. After adjustment for CVD risk factors, including office systolic BP, the adjusted hazard ratios expressing the risk of CVD events were 1.30 (95% confidence interval, 1.15–1.52), 1.27 (1.04–1.56), and 1.25 (1.11–1.40) per one-SD increase in log-transformed urinary albumin creatinine ratio (UACR, 0.57 mg/gCre), brachial-ankle pulse wave velocity (baPWV, 342 cm/s) and left ventricular mass index (LVMI, 26.6 g/m2) assessed by echocardiography, respectively. Even after adding home systolic BP as a covariate, these associations remained except for the association with baPWV (all P < 0.05). The C-statistic for the base model including office and home systolic BP for the risk of CVD events was 0.783 (95% CI: 0.743, 0.824), which significantly increased to 0.795 (95% CI: 0.757, 0.834) after adding LVMI, and changed slightly but not significantly with the addition of UACR or baPWV. Adding UACR, baPWV, or both to the model including LVMI did not improve CVD event prediction. In the modern era of hypertension management using home BP measurement, TOD indicators, especially LVMI, provide superior CVD event prediction independent of and beyond home BP.
KW - Cardiovascular event
KW - Home blood pressure
KW - Left ventricular mass index
KW - Target organ damage
UR - https://www.scopus.com/pages/publications/85129812548
U2 - 10.1038/s41440-022-00927-y
DO - 10.1038/s41440-022-00927-y
M3 - Article
AN - SCOPUS:85129812548
SN - 0916-9636
VL - 45
SP - 1240
EP - 1248
JO - Hypertension Research
JF - Hypertension Research
IS - 8
ER -